ClinicalTrials.gg
CompletedNCT01429116Updated Apr 21, 2015

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

A Phase 3 interventional study of tasimelteon in Non-24-Hour Sleep-Wake Disorder, sponsored by Vanda Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-21.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.

Planned enrollment
13th of 54
200 · median 50
Started
2011
with 3 others
Phase 3
10 of 69
1 open now
Registered
26th of 69
by date
Lead sponsor
6 of 69
Vanda Pharmaceuticals

Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 13th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2011, is one of 10 in phase 3, and was the 26th registered.

Sleep Disorders, Circadian Rhythm

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

Browse Sleep Disorders, Circadian Rhythm studies →

Open to participants now

10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of tasimelteon in male and female patients who suffer from Non-24-Hour Sleep-Wake Disorder.

Read the detailed description

Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier is \< 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping. As time progresses, the endogenous circadian rhythm of sleep-wake propensity in these individuals moves further and further away from the 24-hour light-dark cycle and gradually, these individuals are unable to sleep at night and as a result experience extreme sleepiness during the daytime hours and more frequent naps with a longer duration. Eventually, the sleep-wake time moves back into alignment with the social time for sleep and the individuals sleep well at night and have decreased daytime napping. The alignment between their endogenous circadian rhythms and the 24-hour day is temporary as they are continually drifting later and later each day.

The study is comprised of one 24-month treatment phase, as all subjects enrolled in the trial have already been diagnosed with N24HSWD. Frequency of study visits will depend on the subject's prior length of exposure to tasimelteon; accordingly, subjects will be assigned to one of two groups upon enrollment into the study. The short-term exposure group will consist of subjects for which it is possible at screening that they have been exposed to tasimelteon for less than 6 months. The long-term exposure group will consist of subjects who have more than 6 months of exposure to tasimelteon.

After completion of the 24-month treatment phase, subjects have the option to enroll into the optional open-label extension sub-study for an additional 52 weeks. Frequency of visits will be identical regardless of previous exposure (short term/long term).

03

Conditions studied

  • Non-24-Hour Sleep-Wake Disorder

Keywords

  • Blindness
  • Eye Diseases
  • Nap Disorders
  • Circadian Rhythm Disorders
  • Sleep Disorders
  • Circadian Rhythm Sleep Disorders
  • Dyssomnias
  • Nervous System Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability and acceptance to provide ;
  2. Men or women at least 18 years of age or older who meet one of the following:

    • Has enrolled in VP-VEC-162-3201 (with sponsor approval)
    • Has completed VP-VEC-162-3203
    • Was deemed a non-responder in VP-VEC-162-3203
    • Has enrolled in VP-VEC-162-3203 (with sponsor approval)
    • Has a previous diagnosis of N24HSWD
    • The subject is totally blind and meets the following 5 diagnostic criteria

      • A persistent or recurrent pattern of sleep disruption that is primarily due to an alteration of the circadian system or to a misalignment between the endogenous circadian rhythm and the sleep-wake schedule required by an individual's physical environment or social or professional schedule.
      • The sleep disruption leads to excessive sleepiness or insomnia, or both.
      • The sleep disturbance causes distress or impairment in social, occupational, and other important areas of functioning.

    Specifically: A pattern of sleep-wake cycles that is not synchronized to the 24-hour environment, with a consistent daily drift (usually to later and later times) of sleep onset and wake times.

  3. For US participants only: Males, non-fecund females (i.e., surgically sterilized,if procedure was done 6 months before screening or subject is , without menses for 6 months before screening), or females of using an acceptable method of for a period of 35 days before the first dosing during the study and for one month following the last dose and must have a negative pregnancy test at the screening and baseline visits Note: Women using hormonal methods of birth control must use an additional method of birth control during the study and for one month after the last dose.
  4. Diagnosis of N24HSWD in a previous tasimelteon study;
  5. Willing and able to comply with study requirements and restrictions;

Exclusion criteria

Exclusion Criteria:

  1. History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;
  2. History of intolerance and/or to melatonin or melatonin agonists;
  3. History of drug or alcohol abuse as defined in , Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption of alcoholic drinks (> 40g/day);
  4. Patients having any current suicidal ideation of type 4 or 5 on the C-SSRS at Screening or Baseline;
  5. Patient is at risk of suicide, in the opinion of the Investigator. Evidence of suicide risk could include any suicide attempt within the past year or any other suicidal behavior within the past year;
  6. Current cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;
  7. Clinically significant deviation from normal in vital signs measurements, or physical examination findings at screening or baseline as determined by the clinical investigator;
  8. Pregnant or lactating females;
  9. Smoke more than 10 cigarettes/day;
  10. Exposure to any drug other than tasimelteon, including placebo, within 30 days, 5 half-lives, or the exclusion period given by a previous study in which the patient has participated in, whichever of the three scenarios is longer.
  11. Unwilling or unable to discontinue usage of medication listed in Section 8.2.1;
  12. Any other sound medical reason as determined by the clinical investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    tasimelteon

    20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension

    Drug: tasimelteon

Interventions

  • 20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension

    Also known as: VEC-162

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-Emergent Adverse Events (AEs)

    Treatment-emergent adverse events will be summarized by presenting the number and percentage of patients having any treatment-emergent AE, having an AE in each body system, and having each individual AE.

    Time frame: 24 months + 12 month optional extension

Secondary outcomes

  1. Number of participants with changes in Clinical Laboratory Data

    Standard Serum Hematology and Chemistry tests will be performed at baseline and through the 24 months of treatment

    Time frame: 24 months + 12 month optional extension

  2. Number of participants with newly occurring or worsening ECG abnormalities

    Time frame: 24 months + 12 month optional extension

  3. Number of participants with clinically notable Vital Signs and Body Measurements

    Time frame: 24 months + 12 month optional extension

  4. Number of participants who report a positive result for the Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: 24 months + 12 month optional extension

07

Study locations

22 sites
  • Pulmonary Associates, PA
    Phoenix, Arizona 85006, United States
  • SDS Clinical Trials Inc.
    Orange, California 92868, United States
  • VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area)
    Palo Alto, California 94304, United States
  • St. Johns Sleep Disorder Center - St. Johns Medical Plaza
    Santa Monica, California 90404, United States
  • Radiant Research - Denver
    Denver, Colorado 80239, United States
  • PAB Clinical Research Inc.
    Brandon, Florida 33511, United States
  • Kendall South Medical Center, Inc.
    Miami, Florida 33185, United States
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • Sleep Disorders Center Of Georgia
    Atlanta, Georgia 30342, United States
  • Suburban Lung Associates SC (Chicago Metropolitan Area)
    Elk Grove Village, Illinois 60007, United States
  • The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area)
    Chevy Chase, Maryland 20815, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Michigan Head-Pain Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area)
    Chesterfield, Missouri 63017, United States
  • New York Eye and Ear Infirmary
    New York, New York 10003, United States
  • Ohio Sleep Medicine Institute (Columbus Metropolitan Area)
    Dublin, Ohio 43017, United States
  • Lynn Health Science Institute
    Oklahoma city, Oklahoma 73112, United States
  • Columbia Research Group Inc.
    Portland, Oregon 97239, United States
  • Center for Sleep Medicine at Chestnut Hill Hospital
    Philadelphia, Pennsylvania 19118, United States
  • Consolidated Clinical trials
    Pittsburgh, Pennsylvania 15221, United States
  • SleepMed, Inc. - Columbia
    Columbia, South Carolina 29201, United States
  • Todd J. Swick, M.D., P.A.
    Houston, Texas 77063, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2011
First posted
Sep 5, 2011
Start
Oct 2011
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Last update
Apr 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01429116
Responsible party
Sponsor
First posted
Sep 5, 2011
Start date
Oct 2011
Primary completion
Jan 2015
Completion
Jan 2015
Last update
Apr 21, 2015

Study contacts

Vanda Pharmaceuticals
study director · Vanda Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion